INTRODUCTION {#sec1-1}
============

Cardiac transplant is a well-established option for patients with end-stage heart disease.\[[@ref1][@ref2]\] Although the first cardiac transplant in India took place barely months after the world\'s first in 1967\[[@ref3]\](the world\'s first pediatric heart transplant took place 3 days after the adult), it never took up its rightful place as a viable therapeutic option till recent times. A handful of centers across India now offer this modality.\[[@ref4][@ref5][@ref6][@ref7]\] We sought to describe our early experience with pediatric heart transplantation and follow-up in the current era.

METHODS {#sec1-2}
=======

Waiver of informed consent was granted from the hospital\'s ethics committee. Records of pediatric patients who underwent heart transplant from January 2016 to June 2019 were analyzed. Data have been tabulated and expressed as frequency, mean with standard deviation (SD), and median with range as applicable.

RESULTS {#sec1-3}
=======

Demographics {#sec2-1}
------------

Twenty pediatric patients underwent heart transplant during the study period \[[Table 1](#T1){ref-type="table"}\]. The median age at transplant was 12.4 years (range: 3.3--17.3 years). The median weight was 23.2 kg (range: 10--80 kg). There were thirty patients listed during the study period, of which five expired while listed, three were delisted, and two remained on the list, thereby leaving twenty patients who are the subjects of this study. The median wait-listed time was 3.4 months (range: 1 week--18 months) \[[Figure 1](#F1){ref-type="fig"}\].

###### 

Demographic profile of recipients

  Case number   Age at transplant (years)/sex   Weight (kg) at transplant   Diagnosis       Last follow-up (June 2019)   Ventricular function at last follow-up
  ------------- ------------------------------- --------------------------- --------------- ---------------------------- ----------------------------------------
  1             17.3/female                     43.1                        DCM             Alive                        Normal
  2             7.8/female                      27.7                        DCM             Alive                        Normal
  3             16.6/male                       38                          DCM             Expired                      
  4             15.6/female                     43.5                        RCM             Alive                        Normal
  5             14.6/male                       23                          DCM             Expired                      
  6             17.3/male                       29                          RCM             Expired                      
  7             10.3/male                       20                          DCM             Alive                        Normal
  8             16.3/male                       80                          DCM             Alive                        Normal
  9             15.2/male                       50                          DCM             Alive                        Normal
  10            11.1/male                       21.2                        RCM             Alive                        Normal
  11            13.8/female                     28.7                        DCM             Alive                        Normal
  12            4.5/female                      13                          DCM             Alive                        Normal
  13            8.1/male                        19                          Uhl's anomaly   Alive                        Normal
  14            10.8/female                     20.3                        DCM             Alive                        Normal
  15            3.3/male                        15                          DCM             Alive                        Normal
  16            14.6/male                       25.6                        DCM             Alive                        Normal
  17            16.4/male                       47.3                        DCM             Alive                        Normal
  18            8.3/female                      15.4                        DCM             Alive                        Normal
  19            4.5/female                      10                          DCM             Alive                        Normal
  20            9.9/female                      20                          s/p Glenn       Alive                        Normal

DCM: Dilated cardiomyopathy, RCM: Restricted cardiomyopathy

![The time spent on the wait list for each patient (in months)](APC-13-220-g001){#F1}

Pretransplant workup {#sec2-2}
--------------------

### Echocardiography {#sec3-1}

Dilated cardiomyopathy (DCM) patients (*n* = 15): The mean z score of the left ventricular (LV) end-diastolic dimension was + 3.7 (SD: 1.2) and LV end-systolic dimension was + 4.23 (SD: 1). The mean LV ejection fraction was 17.3% ± 7% at the time of transplant. Six of the 15 patients had noncompaction of the LV. Restricted cardiomyopathy patients (*n* = 3): There was severe diastolic dysfunction associated with thrombi in the right atrium (*n* = 2) and pericardial and pleural effusions (*n* = 3). The biventricular systolic function was normal in two of the three patients. There was mild LV systolic dysfunction in one. Only one patient had pulmonary hypertension (mild). Congenital heart disease (*n* = 2): One patient had Uhl\'s anomaly with severe right ventricular (RV) dysfunction. The second patient, aged 9.9 years, had a bidirectional Glenn shunt for a functional single-ventricle anatomy in infancy. She was lost to follow-up before presenting to us with worsening hyperviscosity syndrome and severe systolic and diastolic ventricular dysfunction.

### Cardiac catheterization {#sec3-2}

[Table 2](#T2){ref-type="table"} shows that cardiac catheterization was performed at the discretion of the clinical team. Pulmonary vasodilator testing with oxygen and intravenous sildenafil (0.4 mg/kg over 10 min) was performed if the transpulmonary gradient was elevated (\>12 mmHg).

###### 

Cardiac catheterization data

  Patient number   Diagnosis   Mean PA pressure (mmHg)   LVEDP (mmHg)   TPG pre/postsildenafil + oxygen   PVRi (WU) pre/postsildenafil + oxygen   CI (L/min/m^2^)
  ---------------- ----------- ------------------------- -------------- --------------------------------- --------------------------------------- -----------------
  5                DCM         39                        17             19/5                              5.59/2.14                               3.6
  6                DCM         42                        25             17/6                              4.53/1.54                               3.2
  16               DCM         34                        11             23/17                             6.6/4.77                                3.28
  18               RCM         21                        13             5/-                               2.43/-                                  2
  20               s/p Glenn   18                        15             3/-                               1/-                                     

DCM: Dilated cardiomyopathy, RCM: Restricted cardiomyopathy, CI: Cardiac index, LVEDP: LV end-diastolic pressure, TPG: Transpulmonary gradient, PVRi: Pulmonary vascular resistance indexed

### Other pretransplant workup {#sec3-3}

Human leukocyte antigen (HLA) panel reactive immunoglobulin (Ig) G antibodies (PRA) for HLA Class 2 antibodies was positive (30%, Class II) in 1 patient out of 17 tested. Recipient cytomegalovirus (CMV) IgG antibody titers were protective in 14 of 19 patients whose reports were available and Epstein--Barr virus (EBV) IgG antibody titers were protective in 6 of 17 available records.

Details of the cardiac transplantation procedures {#sec2-3}
-------------------------------------------------

### Donor-recipient data {#sec3-4}

The most common cause of death in the donor was traumatic head injury. The donor heart was mobilized from within the city in seven of twenty patients. The mean donor age was 19 ± 12.9 years and weight was 38.5 ± 14.9 kg. The mean donor-to-recipient weight ratio was 1.62 ± 0.84 \[[Figure 2](#F2){ref-type="fig"}\]. Four of the twenty donors had moderate LV dysfunction on their preretrieval echocardiograms which responded to titration of inotropes. One donor heart had mild aortic regurgitation. Donor-specific antibody (DSA) testing was obtained in the last ten transplants; all were negative except one.

![The donor-to-recipient weight ratio for each patient. Donor weight was not available for patient \#17](APC-13-220-g002){#F2}

### Cardiac transplant surgery {#sec3-5}

Orthotopic heart transplant was performed by standard bicaval anastomotic technique. After ensuring optimal size and function and no significant valvular lesions, the donor heart was harvested after infusing a single 30 ml/kg dose of custodiol solution. Another dose was repeated if the ischemic time crossed 180 min. The mean cold ischemic time was 178.6 ± 49.7 min (range: 90 min--245 min) \[[Figure 3](#F3){ref-type="fig"}\]. Immunosuppression induction was with intravenous basiliximab (20 mg or 10 mg for recipient weight \<30 kg) and methylprednisolone (30 mg/kg).

![Ischemic time (in minutes) for each patient](APC-13-220-g003){#F3}

Intensive care unit and hospital course {#sec2-4}
---------------------------------------

All patients were received on adrenaline (0.5 mcg/kg/min) and milrinone (0.3 mcg/kg/min) drips and also on fentanyl infusions. Noradrenaline and/or inhaled nitric oxide/sildenafil (0.67/mg/kg/h) was added if required. Pressure control mode ventilation was used. Three patients were placed on mechanical circulatory support (MCS) after coming off bypass (details in section 9.2). The mean intensive care unit (ICU) stay was for 12.1 ± 5.4 days (range: 7--27 days). The mean stay in the ward was 10 ± 5.4 days. The predischarge echocardiogram showed normal biventricular systolic function in all patients except one with mild LV dysfunction.

Induction, maintenance immunosuppression, and other medications {#sec2-5}
---------------------------------------------------------------

Protocol followed was methylprednisolone and basiliximab intraoperatively and tacrolimus, mycophenolate mofetil (MMF), and prednisolone for postoperative maintenance immunosuppression.\[[@ref8]\] Tacrolimus was initiated at 0.5 mg bd (on day 4 posttransplant) and then titrated. MMF was dosed at 20 mg/kg/dose twice daily starting on postoperative day (POD) 1. Prednisolone was given at 2.5--5 mg per day for the first 12 months posttransplant. Valganciclovir, trimethoprim-sulfamethoxazole, and a statin were added to drug regimen by days 4--5.

Postdischarge course {#sec2-6}
--------------------

### Outpatient course {#sec3-6}

The mean follow-up period posttransplant was 2.03 ± 0.97 years (range: 0.02--3.57 years). The scheduled follow-up plan was once every 2 weeks for the first 3 months, then once a month for the next 3 months, and then every 3 months till 1 year posttransplant. Subsequently, follow-up was once every 6 months or sooner as dictated by individual patient needs. Echocardiograms documented normal biventricular function in all surviving patients at the last follow-up. EBV polymerase chain reactions were performed periodically in patients with low titers of EBV antibodies pretransplant. Complete blood count and serum creatinine were obtained 3--6 monthly. We had no instance of elevated creatinine levels in our pediatric patient population. Occasional gastrointestinal disturbances or leukopenia were noted that responded to suspending mycophenolate temporarily. Target serum tacrolimus trough levels posttransplant were 10--12 ng/ml (first 6 months), 8--10 ng/ml (6--12 months), and 7--8 ng/ml beyond 12 months from transplant. The dose was uptitrated in the presence of rejection. Mycophenolate was replaced by everolimus/sirolimus in the presence of coronary allograft vasculopathy (CAV). All surviving patients reported a good quality of life with resumption of all routine activities.

### Biopsies and coronary angiograms {#sec3-7}

Surveillance endomyocardial biopsy was performed at 1 month and then annually posttransplant. Jugular or femoral (for \<25 kg weight) approach was used. Rejection in the biopsies was classified according to the International Society for Heart and Lung Transplantation (ISHLT) consensus statement revised in 2005.\[[@ref9]\] Coronary angiograms were routinely performed on all patients on an annual basis.

Mortality {#sec2-7}
---------

The 30-day and 1-year mortality was 0. Three patients expired between 1 and 2 years posttransplant. Two adolescent boys had confirmed noncompliance with their immunosuppressants. One of them \[patient \#3, [Table 1](#T1){ref-type="table"}\] expired from heart failure due to antibody-mediated rejection (AMR) Grade 2, confirmed on biopsy, while the other \[patient \#6, [Table 1](#T1){ref-type="table"}\] expired before reaching a hospital. The third patient \[patient \#5, [Table 1](#T1){ref-type="table"}\] expired after failed treatment for acute AMR Grade 2 despite compliance. Till the end of the study period (June 2019), the remaining 17 patients are alive and well.

Morbidity {#sec2-8}
---------

### Graft rejection {#sec3-8}

A significant grade of rejection (\> cell-mediated rejection (CMR) 2R or any grade of AMR) was documented through biopsy in 7 patients out of 20 (35%) \[[Figure 4](#F4){ref-type="fig"}\]. Two of the seven had AMR Grade 2 and were symptomatic and both expired. All the others had AMR Grade 1. The tacrolimus dose was adjusted to achieve a higher serum trough level in such patients as none had clinical or echocardiographic evidence of rejection. None of the AMR-positive biopsy patients had DSA testing performed as the transplants were dated before DSA tests were made essential in our protocol. PRA status was negative in all biopsy-positive patients.

![Grades of rejection encountered in patients. The highest grade of rejection seen in every patient has been recorded](APC-13-220-g004){#F4}

### Mechanical circulatory support {#sec3-9}

Preoperatively, one patient (patient \#17) required extracorporeal membrane oxygenation (ECMO) for shock and reduced RV contractility. Postoperatively, three patients required MCS. One patient (patient \#10) had mild biventricular dysfunction and severe pulmonary hypertension after coming off pump, and he was placed on ECMO. He could be decannulated 5 days later. The second patient (patient \#13) received a heart from a donor who had arrested during harvesting. Severe LV dysfunction was noted postcardiopulmonary bypass (CPB), and he was placed on ECMO for 48 h. The third patient (patient \#19) was a critically ill child with DCM who was placed on left ventricular assist device for severe LV dysfunction postoperatively. The left atrium was cannulated for inflow, and the aortic cannula used for CPB was continued for outflow. This child also had an oversized donor (weight ratio: 3.6). As the myocardial edema resolved, the patient was able to be decannulated on POD 5.

### Big heart syndrome {#sec3-10}

This was observed in three patients. The donor-to-recipient weight ratio range was 2--3.6 in these patients. These patients had persistent systemic hypertension and also 1--2 episodes of seizures.

### Hypertension {#sec3-11}

The most common side effect was hypertension; it was seen in seven patients, in one of whom, it was pretransplant. It was associated with seizures (see above) in three patients. It was presumed to be related to the neurohormonal derangement or drug side effect in three patients. The hypertension was controlled by enalapril and/or amlodipine.\[[@ref10]\]

### Posttransplant lymphoproliferative disorder {#sec3-12}

This was seen in one patient (case \#10), 1 year posttransplant. He presented with tonsillar abscesses, which was a manifestation of B-cell myeloproliferative disorder (diffuse large B-cell lymphoma). The patient\'s preoperative EBV antibody titers were low (nonprotective). He was aggressively treated with eight cycles of IV rituximab successfully and is currently clinically stable on a modified immunosuppression regimen with normal cardiac allograft function and negative endomyocardial biopsy.

### Coronary allograft vasculopathy {#sec3-13}

Four patients were diagnosed with CAV (all were Grade 1, ISLHT classification) on the basis of their annual coronary angiograms. Three of the four patients had no prior significant grade of rejection on biopsy, and none had CMV infection posttransplant. One of the four patients likely had preexisting (donor) related disease.

### Pancreatic pseudocyst {#sec3-14}

This was seen in one patient \[patient \#12, [Table 1](#T1){ref-type="table"}\], 9 months posttransplant who presented with depressed appetite, vomiting, and abdominal distension. She underwent successful endoscopic pseudocyst fluid drainage.

### Infections {#sec3-15}

Four patients (20%) had a positive bacterial blood culture in the ICU posttransplant, which were successfully treated with intravenous antibiotics. One \[\#10, [Table 1](#T1){ref-type="table"}\] of the four patients had a sternal infection as well. None of the donor blood cultures were positive. Urinary tract infection (*Escherichia coli* in the urine) was seen in one patient (patient \#12) who presented with fever within the first 3 months posttransplant. There were no other proven bacterial, CMV, or fungal infections seen till the end of the study period.

### Other morbidities {#sec3-16}

Elevated lipid levels were seen in three patients posttransplant, one of whom had preexisting hypothyroidism, obesity, and hyperlipidemia. All three patients are on statins and also appropriate diet. Mild hyperglycemia was observed in two patients \[patient \#12 and 14, [Table 1](#T1){ref-type="table"}\].\[[@ref11]\]

DISCUSSION {#sec1-4}
==========

Pediatric heart transplantation is the standard of care for the management of decompensated heart failure.\[[@ref1][@ref2]\] The ISHLT offers comprehensive guidelines on care of patients.\[[@ref12]\] Few publications sharing their experience and outcome data are from outside the Western world.\[[@ref13]\]

Rejection {#sec2-9}
---------

Recent pediatric heart transplant studies and data from ISHLT database suggest an early (treated) rejection incidence of 15%--22% in the 1^st^ year posttransplant that is improving as management protocols improve over eras.\[[@ref1][@ref14]\] Our case series had two patients with treated rejection between 1 and 2 years of transplant. Paucity of local HLA laboratories, longer wait times to run HLA profiles, as well as financial constraints meant that HLA typing of donors (and prospective crossmatch) were not routinely performed at our center initially. However, our protocol now includes HLA typing of all donors. Flow-based single antigen bead (SAB) testing is performed on prospective recipients with positive (\>10%) PRAs to detect HLA-specific antibodies.\[[@ref15][@ref16]\] With these changes, we are able to perform a virtual crossmatch utilizing the donor HLA profiles and the SAB results of the prospective recipients. We believe that there were elements of local nonavailability/delayed availability of the immunosuppressants as also cost factors that contributed to risk-taking behavior. The two deaths in our series seem avoidable. Noncompliance in the adolescent population is not unexpected. We have, since then, made our pretransplant psychosocial counseling and screening process even more stringent.

Big heart syndrome {#sec2-10}
------------------

This refers to the clinical scenario of a hypertension and seizures seen in a situation of an oversized donor allograft used to pumping into a large body, suddenly encountering "reduced" afterload in the recipient body.\[[@ref17]\] Anticipation of this phenomenon in a patient with a high donor/recipient weight ratio will prevent unnecessary workup of seizures and hypertension.

Posttransplant lymphoproliferative disorder {#sec2-11}
-------------------------------------------

In the pediatric postheart transplant population, posttransplant lymphoproliferative disorder (PTLD) has an incidence of 9%, 15%, and 28% at 3, 5, and 10 years, respectively.\[[@ref18]\] EBV is involved in its etiopathogenesis, and EBV-negative (susceptible) recipients with positive donors are believed to be at the highest risk.\[[@ref18][@ref19]\] Our lone patient with PTLD was EBV negative pretransplant. His donor\'s EBV status was unknown. Our protocol is now modified to include donor\'s EBV and CMV IgG titers.

Coronary allograft vasculopathy {#sec2-12}
-------------------------------

This is a much-feared complication of transplant and leading cause of death long term. Its incidence is 13%, 25%, and 54% at 1, 5, and 10 years posttransplant.\[[@ref20][@ref21][@ref22]\] Our four patients with CAV (Grade 1) were placed on daily mammalian target of rapamycin kinase inhibitors everolimus or sirolimus instead of mycophenolate. All our transplant patients are placed on rosuvastatin posttransplant. We have now changed our protocol to include coronary angiography at the 1-month biopsy as well to delineate donor-derived coronary disease in donors older than 40 years. This will also allow us to identify "rapidly progressive CAV" which carries an exponentially higher mortality.\[[@ref23]\]

Pancreatic pseudocyst {#sec2-13}
---------------------

Pancreatic pseudocyst is a known complication postorgan transplant.\[[@ref24][@ref25]\] The pancreatic pseudocyst in our patient was presumed to be a complication of previous episodes of asymptomatic/chemical pancreatitis, perhaps resulting from immunosuppression.

Infections {#sec2-14}
----------

Infections were not a major morbidity in our cohort, beyond 1 month posttransplant. Our experience of 20% infection rate (bacterial) immediately posttransplant is consistent with published data.\[[@ref26]\] Our instructions to families are to minimize visitors to zero for a month postdischarge home and to minimize stepping out of the house for the first 6 months. School going children are encouraged to home school for that period. The diet for immunosuppressed patients is followed for the first 12 months posttransplant. These may have been factors in reducing infection rate in our cohort.

Hyperlipidemia {#sec2-15}
--------------

Hyperlipidemia is prevalent in 60%--80% of posttransplant patients. Statins may help with hyperlipidemia and also increase in survival posttransplant, reduction in rate of rejection, PTLD, and CAV.\[[@ref27][@ref28]\] We place all our transplant patients on rosuvastatin posttransplant.

Limitations of the study {#sec2-16}
------------------------

Small cohort size, retrospective data collection and missing data points, insufficient long-term follow-up, and an evolving management protocol are the limitations of the study. It is also beyond the scope of this study to discuss the economics of heart transplant in our limited resource setting of a limited resource country.

CONCLUSION {#sec1-5}
==========

The results suggest acceptable short-term outcomes in Indian pediatric patients after heart transplantation in the current era. Significant rejection episodes and CAV need careful follow-up as do concerns of infections in the long term.
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